Ann: Antisense Therapeutics CEO announces retirement, page-50

Timely announcement.

I just hope the Board think through this succession carefully.

We don't need another Mark, we also don't need someone like Anthony (with all due respect).

The Board needs to search globally for someone with BigPharma experience and capital markets connections.

The pivot towards the US strategy is now almost complete - what recent development has caused this?

Phase 2B, monkey tox study, new CEO....potential NASDAQ listing.

We'll now have two critical workstreams up and running - add to that the Combo lab results due soon, and all roads lead to Sarepta maybe wanting to play ball for the US market.

.